Abstract
The Brugia Test Plus (BT+) is a new rapid diagnostic test for Brugia species which detects human IgG4 antibodies specific for the immunogenic Brugia protein BmR1. The aim of this study was to evaluate the BT+ assay with several types of sample-matrices: whole blood, plasma, and dried blood spots (DBS) from individuals living in Belitung Timur, a Brugia malayi endemic area in Indonesia. Night blood was collected from residents living in four presumed endemic villages, while DBS were collected from schoolchildren living in those four villages. The sensitivity of BT+ was measured by comparing the BT+ results to microscopic examination for microfilaria (Mf). The sensitivity of BT+ with whole blood under field conditions was 84.9% (95% CI 68.1–94.9, n = 33), and with EDTA plasma under laboratory conditions was 95.9% (95% CI 88.5–99.1, n = 73). Specificity was not assessed as it is impossible do so for an antibody test in endemic areas. In Mf-negative individuals, BT+ detected IgG4 antibodies in 204 out of 1,547 adult plasma samples (13.2%) and 7 out of 146 plasma samples collected from children aged 10–16 (4.8%). Detection of IgG4 antibodies in DBS collected from first and second grade schoolchildren (age 6–8) showed that only 1 out of 244 schoolchildren was positive (0.1%). Three individual readers were responsible for reading the BT+ . Statistical analysis showed high agreement among those readers (Kappa agreement value above 0.9). Laboratory technicians found the BT+ is simple to perform, easy to interpret the results, and appreciated the small volume of blood required (5 µL). This study has demonstrated that the novel BT+ is feasible for teams to implement and achieves good sensitivity, making it well suited for monitoring and evaluating the progress of the brugian- filariasis elimination program.
Author summary
The Brugia Test Plus (BT+) is a new rapid diagnostic test for Brugia species that detects human IgG4 antibodies directed against the Brugia protein BmR1. BT+ was evaluated in the field using a variety of samples, including whole blood, plasma, and dried blood spots (DBS) from people living in Belitung Timur, an endemic area for Brugia malayi in Indonesia. Night blood samples were collected from residents of four endemic villages, and day blood samples for DBS were obtained from schoolchildren in same villages. The sensitivity of BT+ was determined by comparing its results to a microscopic test for microfilaria (Mf). BT+ had a sensitivity of 84.9% with whole blood in the field and 95.9% with EDTA plasma in the lab. Specificity was not evaluated in B. malayi endemic area. Overall, the BT+ was found to be straightforward to perform and interpret, and its analytic performance is well suited for measuring the impact of the brugian-filariasis elimination program.
Introduction
Lymphatic filariasis (LF) caused by the three filarial species, Wuchereria bancrofti, Brugia malayi, and Brugia timori, is a public health problem in Indonesia. According to reports, LF is endemic in 236 out of 514 districts or cities in Indonesia, with Brugia malayi being the dominant parasite, which is endemic in 189 of these areas [1]. Infections caused by these filarial worms result in lifelong disabilities, leading to physical and psychological distress as well as significant socio-economic disruption for the affected individuals [2].
To combat LF, the World Health Organization (WHO) launched a global elimination program with the goal of eliminating the disease by 2030 [3]. A Mass Drug Administration (MDA) strategy was implemented to achieve the goal, with the current WHO recommendation being a triple drug therapy of ivermectin (200 µg/kg body weight), diethylcarbamazine citrate (DEC, 6 mg/kg body weight), and albendazole (400 mg). This combination is administered annually for two consecutive years and was introduced as a replacement for the previous regimen of DEC 6 mg/kg body weight and albendazole 400 mg, which required five years of administration [4].
Indonesia has been actively participating in the global LF elimination program since 2002, implementing MDA with DEC 6 mg/kg body weight and albendazole 400 mg annually for at least five consecutive years among residents of endemic districts or cities. To evaluate the success of the elimination program, it is crucial to use diagnostic tools that are sensitive, specific, reliable, and suitable for field use. The detection of anti-filarial IgG4 antibodies, which serve as markers of active Brugia infection or exposure, has been recommended by WHO for monitoring and evaluating LF elimination efforts in Brugia endemic areas [5–7].
However, the current serological diagnostic tool (Brugia Rapid Test) [8] widely used for monitoring and evaluating brugian filariasis elimination programs has shown inconsistent results in detecting infected individuals. This inconsistency is mainly due to significant lot-to-lot variability in sensitivity. Therefore, it is essential to develop diagnostic tools with improved consistency for reliable detection of IgG4 antibodies in communities following mass treatment.
A new diagnostic tool, Brugia Test Plus (BT+), developed by Drugs & Diagnostics for Tropical Diseases, San Diego, California, has been previously tested at Washington University School of Medicine in St. Louis using 65 archived plasma samples from individuals with B. timori microfilaremia from Alor (Indonesia) and 36 samples of individuals from Uganda, Germany and the USA (non-endemic areas for brugian filariasis), and showed promising results with sensitivity and specificity of 100%. The objective of this study was to evaluate the novel diagnostic tool in the field by comparing its sensitivity to the conventional/standard diagnostic tool, namely microscopic examination of thick blood smears. The study was conducted in Belitung Timur district, a B. malayi endemic area, where the local LF elimination program started in 2005.
Methodology
Study approval
Verbal informed consent was obtained from all adult participants. For child participants, verbal assent was obtained from their legal guardians, teacher, and the head of Primary Health Center. This study received an ethical approval from Universitas Indonesia (Approval No. KET-631/UN2.F1/ETIK/PPM.00.02/2023).
Study area
Belitung Timur district, an endemic area for LF caused by B. malayi, has been the focus of LF elimination through MDA with a combination drug of DEC and albendazole since 2005. Despite these efforts, the district failed to pass the Transmission Assessment Survey (TAS) in 2014 using IgG4 antibody detection, Brugia Rapid Test, in schoolchildren, prompting two additional rounds of DEC-albendazole treatments. Subsequent evaluations, including pre-TAS assessments using night thick blood smears, followed by TAS (1 and 2) assessments through detection of IgG4 antibodies in first- and second-grade schoolchildren (age 6–8), demonstrated that Belitung Timur successfully passed these evaluations. However, the district was unable to proceed to TAS 3 due to the lack of reliable diagnostic tools for IgG4 antibody detection at that time [9,10].
Belitung Timur district consists of 39 villages with a total population of 132,355. A preliminary survey (Survey 1) was conducted in May 2023 in 16 villages across six primary health centres (Fig 1). These villages were strategically selected due to their proximity to other B. malayi endemic areas in the neighbouring Belitung district, making them important locations for assessing the success of LF elimination efforts. Out of the 16 surveyed villages, 14 were identified as endemic by thick blood smear from night blood collection (Table 1).
Fig 1. Map of the study area in Belitung Timur District, Indonesia.
Belitung Island is divided into two districts: Belitung District (left) and Belitung Timur District (right). The study area, Belitung Timur District, includes sixteen labeled study villages. Among these, fourteen were classified as endemic (highlighted in pink) and two were non-endemic (in yellow). From the endemic villages, four high-endemicity villages were chosen for the Brugia Test Plus diagnostic assessment (red dots). Base map layer sourced from GADM for Indonesia (https://gadm.org/download_country.html, select “Indonesia”) and used under the GADM license (https://gadm.org/license.html). Map created using QGIS.
Table 1. Crude prevalence of lymphatic filariasis in 16 villages of Belitung Timur district.
| Primary Health Center | Village | No. Mf+ | Total sample | Prevalence (%) |
|---|---|---|---|---|
| Damar | Air Kelik | 0 | 115 | 0 |
| Dendang | Balok | 5 | 328 | 1.52 |
| Dendang | 6 | 100 | 6.00 | |
| Jangkang | 6 | 615 | 0.98 | |
| Nyuruk | 7 | 472 | 1.48 | |
| Gantung | Jangkar Asam | 5 | 139 | 3.6 |
| Limbongan | 3 | 308 | 0.97 | |
| Selinsing | 0 | 217 | 0 | |
| Kelapa Kampit | Buding | 3 | 135 | 2.22 |
| Cendil | 4 | 171 | 2.34 | |
| Simpang Pesak | Dukong | 2 | 141 | 1.42 |
| Simpang Pesak | 2 | 126 | 1.59 | |
| Simpang Renggiang | Air Madu | 7 | 185 | 3.78 |
| Lintang | 6 | 492 | 1.22 | |
| Renggiang | 3 | 133 | 2.26 | |
| Simpang Tiga | 2 | 116 | 1.72 | |
| Total | 61 | 3793 | 1.61 |
Further night blood collection in June 2023 (Survey 2) was conducted in four endemic villages -Buding, Renggiang, Jangkar Asam, and Dendang – where Mf prevalence exceeded 1% [11]. The study aimed to collect samples from the populations living in the LF endemic areas, targeting at least 300 individuals per village based on the minimum sample size required for pre-TAS [11]. Participants were distributed across household groups knows as Rukun Tetangga (RT), the smallest administrative unit within the village governance system. For example, in a village with 10 RTs (RT 1 to RT 10), 30 participants were randomly selected from each RT.
Blood sample collection
This study employed two different sample collection methods: night blood collection targeted communities and day blood collection targeted schoolchildren.
Night blood collection.
For community participants, approximatively 250 µL of night blood was collected between 8:00 PM and 12:00 AM by a finger pick and stored in an EDTA tube (Microtainer Tube, BD, New Jersey, USA). From this sample, 60 µL was used to prepare a thick smear for microscopic examination, which increase the chance of detecting microfilariae, especially important in areas where MDA has been conducted [11]. The remaining blood was centrifuged to separate the plasma, which was then transferred into new tubes and stored at -20°C. These plasma samples were transported to Jakarta under cold conditions and stored at -20°C in the laboratories of the Department of Parasitology, Faculty of Medicine, Universitas Indonesia, for IgG4 antibody detection.
All microfilaremic patients identified in the preliminary survey were included in the night blood collection for this study. Those samples (n = 61) with additional Mf-positive individuals found in this study (n = 12) were recruited for a sensitivity assay, comparing the presence of Mf detected by microscopy of blood smears and IgG4 antibody detection using the BT+ test.
Day blood collection.
The dried blood spot (DBS) technique was used to collect samples from grade 1 and grade 2 elementary school children living in four selected villages (Buding, Renggiang, Jangkar Asam, and Dendang). A total of 244 children from seven elementary schools participated in the blood collection. Samples were taken during the daytime (8:00 AM–10:00 AM) at their schools. Blood was drawn by puncturing a fingertip with a sterile disposable lancet. The first drop of blood was wiped away with a gauze pad to remove excess tissue fluid. The fingertip was then massaged to stimulate blood flow, and the next drop was transferred onto one of the circles on a labelled filter disk (TropBio cat. no. FP). The blood was absorbed into the filter by capillary action, and this process was repeated to create six blood spots per child, each spot containing 10 µL of blood. Once air-dried, the filters were stored individually in plastic bags with desiccants at room temperature and then stored at -20°C for further use.
Thick Blood Smear
Three lines of blood smear were prepared on a slide from each sample, with each line containing 20 µl of blood [11]. After air-drying, the blood was haemolysed, fixed with methanol, and stained with Giemsa. The stained slides were examined under a microscope to determine the Mf count in 60 µl of blood. Two independent technicians at Universitas Indonesia were assigned to examine the slides. The Mf count was reported based on the total number of Mf found in three blood lines.
IgG4 antibody detection by Brugia Test Plus
Whole blood samples.
For the sensitivity testing of BT+ , we compared fresh whole blood, EDTA-treated blood, and plasma samples to evaluate two factors: first, whether the use of EDTA as an anticoagulant affects the sensitivity of BT+ ; and second, whether 2.5 µL of plasma provides comparable sensitivity to 5 µL of fresh whole blood. Thick blood smears with known microfilariae (Mf) counts, confirmed by microscopic examination, were used as the gold standard. A total of 10 Mf-positive samples were included in this evaluation.
Plasma samples.
The Brugia Test Plus (BT+) was used to detect the presence of anti-filarial IgG4 antibodies in plasma samples from the population. The test was conducted at the Laboratory of Parasitology, Universitas Indonesia, Jakarta, in accordance with the manufacturer’s instructions. A 2.5 µL volume of plasma was applied to the sample port, followed by the addition of three drops of buffer solution to the rectangular buffer port. To ensure accuracy and consistency, the results were read after 25 minutes by three independent readers, each within a three-minute window. A result was considered positive or negative when two of the three readers provided the same binary interpretation. In addition, we visually graded the intensity of the test line using a simple ordinal scale (absent, shadow, weak, medium, strong). Given concerns about reduced sensitivity in low-level infections during post-MDA surveillance, this grading was used to explore whether line strength could act as a proxy for infection intensity and to assess test performance at low Mf counts.
Dried blood samples.
A 96-well plate was used to elute the dried blood spot samples. 100 µL of chase buffer was added into each well of the plate, and then 1 circle of dried blood spot from each individual was added to each well. After incubating for one hour at room temperature, 10 µL of eluted dried blood spot (DBS) was added to the sample port. Three drops of buffer solution were then added to the rectangular buffer port. The results were read after 25 minutes of incubation by three independent readers, following the same procedure used for the plasma samples.
Statistical analysis
Data, including name, gender, age, village name, Mf count, and BT+ result, were entered into an Excel file. Statistical analysis was performed using SPSS version 20. The comparison between the prevalence rates of Mf and IgG4 tested by BT+ was conducted using the McNemar test. The agreement among three readers who read the BT+ results was analysed using Cohen’s kappa agreements.
Results
Sixteen villages in Belitung Timur were screened using night blood smears to assess the Mf prevalence. Most of these villages are located near the Belitung district. The flow of study participants is shown in Fig 2 (Survey 1). The results from preliminary survey revealed that 14 out of the 16 villages are endemic for LF (Table 1). A total of 61 Mf-positive patients were identified in these 14 endemic villages, comprising 60 adults and one 14-year-old boy.
Fig 2. The flow of study participants in Belitung Timur.
Two villages, Limbongan and Jangkang, had the lowest Mf rates, at 0.97% and 0.98%, respectively. The Mf prevalences in the remaining 12 villages ranged from 1.22% to 6%. For this study, four endemic villages were chosen: Dendang (6% Mf rate), Jangkar Asam (3.6%), Buding (2.22%), and Renggiang (2.26%). The selection of these villages was based on the presence of elementary schools, which facilitate the collecting of the day blood samples from schoolchildren.
Characteristics of samples
A night blood collection was conducted among residents of four endemic villages (1,705 individuals, Table 2) including 61 individuals identified as Mf+ in a previous survey (Table 1). Among these individuals, 907 (51.4%) were male and 859 (48.6%) were female.
Table 2. Percentage of Mf+ in each endemic village.
| Primary Health Center |
Village | Children (≤ 17 years) |
Adults (> 17 years) |
No. Mf+ (Prevalence %) |
Total |
|---|---|---|---|---|---|
| Dendang | Dendang | 42 (12.77%) | 287 (87.23%) | 2 (0.61%) | 329 |
| Gantung | Jangkar Asam | 42 (9.38%) | 406 (90.63%) | 3 (0.67%) | 448 |
| Kelapa Kampit | Buding | 32 (6.81%) | 438 (93.19%) | 4 (0.85%) | 470 |
| Simpang Renggiang | Renggiang | 30 (6.55%) | 428 (93.45%) | 3 (0.66%) | 458 |
| Total | 146 (8.56%) | 1559 (91.44%) | 12 (0.70%) | 1705 |
Microscopic examination of the population revealed that 12 out of the 1,705 individuals were Mf-positive, resulting in the Mf rate ranging from 0.61% to 0.85% (Table 2). All microfilaremic patients were adults and were distributed across the villages as follows: Dendang (2 patients), Jangkar Asam (3 patients), Buding (4 patients), and Renggiang (3 patients). No Mf-positive children were observed in those four endemic villages.
Sensitivity of BT+ using whole blood, with or without EDTA
The BT+ test was evaluated in the field as per manufacturer’s instructions (S1 Fig) using fresh fingerstick blood, devoid of any anticoagulant, from 23 Mf-positive persons with Mf densities ranging from 1 Mf/60 µL to 85 Mf/60 µL. A total of 19 of 23 patients showed anti-filarial IgG4 antibodies. Another 10 Mf-positive individuals had further tests done using freshly collected fingerstick blood, but this time with EDTA as anticoagulant. Of these, 9/10 patients were positive for BT+. Furthermore, on a limited number of patients, it was shown that whole blood behaves similarly whether containing EDTA or no anticoagulant (Fig 3). Hence, when combining the data without (n = 23) and with EDTA (n = 10), the sensitivity of the BT+ assay was 28/33, or 84.9% (95% CI 68.1-94.9, n = 33). The assay detected antibodies in all the samples that had at least 2 Mf/60 µL and had difficulties detecting only 1 Mf/60 µL (Fig 4).
Fig 3. Comparison of Fingerstick blood with and without anticoagulant on the same subject.
Row A and B show BT+ from blood samples without anticoagulant in duplicates while row C shows BT+ from EDTA-treated blood.
Fig 4. Appearance of the test line when run with fresh blood, without anticoagulants, compared to Mf density.
Sensitivity of BT+ when using plasma (from EDTA blood)
A total of 73 sera samples from Mf-positive individuals identified by microscopic examination of nighttime thick blood smear (61 Mf-positive cases from previous survey and 12 Mf-positive cases from this study, as shown in Tables 1 and 2), consisting of 61 males and 12 females, were tested for the presence of anti-filarial IgG4 antibodies using the BT+ assay (Table 3).
Table 3. Percentage of anti-filarial IgG4 positivity in microfilaremic patients based on gender.
| Mf count per 60 µL | Female | Male | ||||
|---|---|---|---|---|---|---|
| Mf+ | BT+ Positive | BT+ Negative | Mf+ | BT+ Positive | BT+ Negative | |
| 1–10 | 7 | 7 | 0 | 30 | 28 | 2 |
| 11–20 | 2 | 2 | 0 | 15 | 14 | 1 |
| 21–30 | 2 | 2 | 0 | 7 | 7 | 0 |
| 31–40 | 0 | 0 | 0 | 4 | 4 | 0 |
| 50–100 | 1 | 1 | 0 | 4 | 4 | 0 |
| >100 | 0 | 0 | 0 | 1 | 1 | 0 |
| Total % |
12 | 12 (100%) |
0 (0%) |
61 | 58 (95.1%) |
3 (4.9%) |
The Mf counts among the participants varied from 1 Mf/60 µL to 129 Mf/60 µL. Of these, four patients had a low Mf count of 1 Mf/60 µL; two of these low Mf patients tested positive for IgG4 antibodies by the BT+ assay, while the other two showed a negative result. Additionally, one patient with an Mf count of 12 Mf/60 µL also showed negative for IgG4 antibodies. All three IgG4-negative cases were male participants, whereas all female Mf-positive participants tested positive for IgG4 antibodies.
In total, 3 out of the 73 microfilaremic patients (4%) were negative for IgG4 detection by BT+ , with two of the three negatives only having 1 Mf/60 µL by microscopy. Overall, this study showed that the BT+ assay successfully detected anti-filarial IgG4 antibodies in 70 out of 73 microfilaremic patients, resulting in a sensitivity of 96%. These findings demonstrate the high sensitivity of the BT+ assay in identifying B. malayi infections.
It should be noted that although the study was not powered to provide statistically significant data regarding matrix equivalence, it appears that when close to the limit of detection, the sensitivity is somewhat better with plasma than with DBS or whole blood (Fig 5).
Fig 5. Comparison of 3 matrices from the same patient with EDTA whole blood (A), EDTA plasma (B), and DBS (C).

Whole blood and DBS give very tenuous test lines, while plasma gives a more easily visible test line.
Detection of IgG4 antibody in all Mf negative samples
BT+ was also used to detect the presence of anti-filarial IgG4 antibodies in all Mf-negative participants from the study population. A total of 1,693 samples from 146 children aged 6–17 years old and 1,547 adults aged 18–90 years old, who were confirmed Mf-negative by microscopic examination of thick blood smears, were examined for the positivity of IgG4 antibodies. The results showed that 211 samples (7 from children aged 10–16 years old and 204 from adults) were positive for IgG4 antibodies using the BT+ assay. This indicated a prevalence of IgG4 positivity of 4.79% (7/146) in children and 13.19% (204/1,547) in adults (Table 4).
Table 4. Percentage of IgG4 positivity in Mf negative individuals.
| Village | Children (<=17 Years) | Adults (>17 Years) | Total (%) | ||
|---|---|---|---|---|---|
| Mf Negative | BT+ Positive (%) | Mf Negative | BT+ Positive (%) | ||
| Dendang | 42 | 1 (2.4%) | 285 | 30 (10.5%) | 327 (9.5%) |
| Jangkar Asam | 42 | 1 (2.4%) | 403 | 54 (13.4%) | 445 (12.4%) |
| Buding | 32 | 4 (12.5%) | 434 | 61 (14.1%) | 466 (13.9%) |
| Renggiang | 30 | 1 (3.3%) | 425 | 59 (13.9%) | 455 (13.2%) |
| Total | 146 | 7 (4.8%) | 1547 | 204 (13.2%) | 1693 (12.5%) |
Detection of IgG4 antibodies from dried blood spot samples of school children
A total of 244 grade 1 and grade 2 schoolchildren (age 6–8 years) from seven elementary schools participated in the day blood collection. The BT+ results revealed that only one child from Dendang’s elementary school tested positive for IgG4 antibodies (Table 5).
Table 5. Brugia Test Plus results from seven elementary schools.
| Village | School | BT+ Positive | BT+ Negative | Total |
|---|---|---|---|---|
| Buding | SDN 1 Kelapa Kampit | – | 29 | 29 |
| SDN 10 Kelapa Kampit | – | 24 | 24 | |
| SDN 7 Kelapa Kampit | – | 36 | 36 | |
| Dendang | SDN 1 Dendang | 1 | 53 | 54 |
| Jangkar Asam | SDN 15 Gantung | – | 59 | 59 |
| Renggiang | SDN 5 Renggiang | – | 24 | 24 |
| SDN 6 Renggiang | – | 18 | 18 | |
| Total | 1 (0.41%) | 243 (99.59%) | 244 (0.41%) |
There were nine school children—three from Dendang Village, one from Jangkar Asam village, and five from Renggiang Village—who also participated in the night blood collection. The BT+ test using 2.5 µL of plasma yielded the same negative results as the BT+ test using DBS samples.
Agreement in reading the Brugia Test Plus among three readers
In this study, three independent readers (Table 6) were assigned to interpret the results of the BT+ . Out of the 1,766 samples tested with BT+ , only 27 samples (1.53%) showed differences in reader interpretation either positively or negatively. Crosstabs statistical analysis was used to calculate the agreement among the readers. The results showed that the kappa agreement value between readers 1 and 2 was 0.964, between readers 1 and 3 was 0.945, and between readers 2 and 3 was 0.977. The overall agreement among all raters was 0.962 as measured by Fleiss’ kappa, indicating almost perfect agreement.
Table 6. Pairwise inter-reader agreement in BT+ interpretation.
| Reader 1 | Reader 2 | Reader 3 | |||||
|---|---|---|---|---|---|---|---|
| BT+ Pos | BT+ Neg | BT+ Pos | BT+ Neg | BT+ Pos | BT+ Neg | ||
| Reader 1 | BT+ Pos | 271 (15.3%) |
6 (0.3%) |
266 (15.1%) |
11 (0.6%) |
||
| BT+ Neg | 11 (0.6%) |
1478 (83.7%) | 15 (15%) |
1474 (83.5%) | |||
| Reader 2 | BT+ Pos | 276 (15.6%) |
6 (0.3%) |
||||
| BT+ Neg | 5 (0.3%) |
1479 (83.7%) |
|||||
Discussion
In regions where brugian filariasis is endemic, an anti-filarial IgG4 antibody test is important to monitor the success of elimination programs, since it shows past and/or recent infection.
The utility of detecting anti-filarial IgG4 antibodies to BmR1 was first demonstrated by Noordin et al more than 20 years ago [8]. A rapid test based on that technology and commercialized by Reszon Diagnostics was investigated in multicentre studies and showed 99% specificity and 95% sensitivity for detecting IgG4 antibodies in B. malayi-infected samples [8,12]. Field evaluations comparing the Brugia Rapid Test with microscopic examination of thick blood smears revealed a sensitivity of 87% and a specificity of 100% [13].
The IgG4 antibody detection can be used in LF-endemic areas, whether caused by Brugia malayi or Brugia timori. Several studies have demonstrated the advantages of IgG4 antibody detection in assessing the endemicity of brugian-filariasis. For instance, research conducted in B. malayi endemic areas comparing micropore filtration (examined under a microscope) with IgG4 antibody detection showed that when Mf prevalence by microscopy was 6–7%, the seroprevalence was 46.9%. This demonstrates its ability to detect previous or amicrofilaremic infections [14]. Similarly, a study in B. timori endemic areas in Alor District revealed an 81% seroprevalence using IgG4 antibody detection, compared to 26% Mf prevalence by the nucleopore filtration method [15]. These discrepancies between IgG4 results and Mf prevalence are to be expected and demonstrate the sensitivity of IgG4 testing in detecting very low parasite loads or single-sex (only male or female) worm infections, as well as cryptic infections, past and/or recent infection. Furthermore, a serological test can be performed using blood collected during the day, which is a major programmatic advantage over collecting nighttime blood. These findings indicated the usefulness of the IgG4 test in evaluating the progress of filariasis elimination efforts [6,16].
Although the original test was easy to use in the field, there have been issues with sensitivity varying across different production batches. This inconsistency has made it difficult for program managers to rely on the test for monitoring elimination programs in brugian filariasis-endemic areas. The BT+ test, with a sensitivity of 96% compared to Mf positive subjects, is a novel assay that detects IgG4 specific for BmR1 and offers an alternative method for testing.
The BT+ assay was able to identify the existence of anti-filarial IgG4 antibody in microfilaremic patients with the lowest Mf count of 1–2 Mf/60 µL, but the sensitivity was only 33%. The fact that the test is sensitive even in samples containing only 1–2 Mf/60 µL seems to justify its use in areas of low endemicity. Taken together, these findings suggest that the BT+ assay will be essential for evaluating the effectiveness of the elimination program after mass drug administration (MDA) in endemic areas.
From an epidemiological standpoint, among 1,693 Mf-negative individuals, 211 individuals were anti-filarial IgG4 antibody positive (12.46%). Among the IgG4 positive individuals, adults were more likely positive compared to children. Nearly all the positive children were 10–16 years old; only one was 6–8 years old. Therefore, it appears that the risk of exposure to filarial infections increases with age. As a result, in endemic areas, adults have a higher percentage of positive BT+ than 10–16-year-old children, which in turn have a higher seroprevalence than 6–8-year-old children who are the target population of TAS [17]. This finding raises questions with regard to the optimal age group to be used as sentinel groups to evaluate effectiveness of the elimination program, and adults or older children may be a better sentinel group than young children.
Many endemic areas for lymphatic filariasis (LF) are difficult to access, and transporting blood samples from these locations poses significant challenges. The development of the dried blood spot (DBS) method offers a practical alternative to traditional blood collection methods, such as microtainers or vacutainers. In this study, filarial IgG4 antibodies were successfully detected in day blood samples collected on DBS from schoolchildren. A previous study conducted in Alor, an area endemic to Brugia timori, supported these findings by demonstrating a higher rate of filarial IgG4 antibodies detected on DBS in 17 individuals, of whom 8 individuals were Mf-positive and 9 were PCR-positive. These findings underscore the simplicity and scalability of the DBS method for sample collection in elimination programs, as well as the effectiveness of BT+ in detecting filarial IgG4 antibodies in DBS.
Evaluating the level of agreement among the readers is essential to determine the reliability and ease of interpreting the BT+ results. This study showed high agreement among readers of BT+ results, demonstrating that the BT+ is easy to interpret visually by naked eyes, and indicating a high degree of consistency. These results support the usability of BT+ in diverse settings, reinforcing its reliability for detecting low levels of infection.
The new format diagnostic tool BT+ requires significantly less sample volume than the previous format for detecting anti-filarial IgG4 antibodies in both Mf-positive and Mf-negative individuals. It needs only a 5 µL blood sample or a 2.5 µL plasma/serum sample [18]. In addition to the reduced sample volume, the BT+ assay is easy to perform and to interpret the results based on high contrast test lines. These advantages make BT+ a more practical and efficient tool for detecting filarial infections, particularly after mass drug administration in brugian filariasis-endemic areas.
A limitation of this study is that the stability of test under higher temperature for transporting and storage of test to/in the field need to be tested since the endemic areas are usually in hot climate (more than 30°C), which has exceeded the maximum temperature allowed by the manufacturer.
Supporting information
Instructions for use with whole blood and dried blood spot (DBS) samples.
(PDF)
This file contains data from survey 2 (communities and school children) used for figures and tables.
(XLSX)
Acknowledgments
We would like to express our sincere gratitude to Sudirman for his dedication in this study. We would also like to thank the Ministry of Health, Indonesia, local health district staffs, local primary health center staff, and local nursing students for their hard work and commitment in the field work. Special thanks to the local residents for their participations in the study.
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
Funding Statement
This study is funded by Coalition for Operational Research on Neglected Tropical Diseases (COR-NTD). The initial of the author who received the award is TS, with the grant numbers of NTD SC-257G. The funders played role in the study design and preparation of the manuscript by editing and reviewing. However, they had no role in data collection and analysis. URL: https://www.cor-ntd.org/.
References
- 1.Ministry of Health Republic of Indonesia. Sejumlah Penyakit Tropis Ini Harus Diwaspadai. 2023 [cited 2024 Sept 29]. https://sehatnegeriku.kemkes.go.id/baca/rilis-media/20230130/1642296/sejumlah-penyakit-tropis-ini-harus-diwaspadai/
- 2.Barrett C, Chiphwanya J, Chaponda L, Matipula DE, Turner JD, Taylor MJ, et al. Mental health conditions in people affected by filarial lymphoedema in Malawi: prevalence, associated risk factors and the impact of an enhanced self-care intervention. Int Health. 2023;15(Supplement_3):iii14-27. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.NTD Modelling Consortium Lymphatic Filariasis Group. The roadmap towards elimination of lymphatic filariasis by 2030: insights from quantitative and mathematical modelling. Gates Open Res. 2019;3:1538. doi: 10.12688/gatesopenres.13065.1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Weil GJ, Jacobson JA, King JD. A triple-drug treatment regimen to accelerate elimination of lymphatic filariasis: From conception to delivery. Int Health. 2020;13(Supplement_1):S60-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Oqueka T, Supali T, Ismid IS, Purnomo, Rückert P, Bradley M, et al. Impact of two rounds of mass drug administration using diethylcarbamazine combined with albendazole on the prevalence of Brugia timori and of intestinal helminths on Alor Island, Indonesia. Filaria J. 2005;4:5. doi: 10.1186/1475-2883-4-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Supali T, Djuardi Y, Bradley M, Noordin R, Rückert P, Fischer PU. Impact of six rounds of mass drug administration on Brugian filariasis and soil-transmitted helminth infections in eastern Indonesia. PLoS Negl Trop Dis. 2013;7(12):e2586. doi: 10.1371/journal.pntd.0002586 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Supali T, Djuardi Y, Lomiga A, Nur Linda S, Iskandar E, Goss CW, et al. Comparison of the Impact of Annual and Semiannual Mass Drug Administration on Lymphatic Filariasis Prevalence in Flores Island, Indonesia. Am J Trop Med Hyg. 2019;100(2):336–43. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Rahmah N, Taniawati S, Shenoy RK, Lim BH, Kumaraswami V, Anuar AK, et al. Specificity and sensitivity of a rapid dipstick test (Brugia Rapid) in the detection of Brugia malayi infection. Trans R Soc Trop Med Hyg. 2001;95(6):601–4. doi: 10.1016/s0035-9203(01)90091-4 [DOI] [PubMed] [Google Scholar]
- 9.Santoso SA, Taviv Y, Yuliani RD, Mayasari R, Supardi. Community compliance to filarial mass drug administration in Belitung Timur regency. Indonesian Bulletin of Health Research. 2010;38(4):185–97. [Google Scholar]
- 10.Central Agency of Statistics Indonesia. Jumlah Kabupaten/Kota Endemis Filariasis yang Mencapai Eliminasi, 2021-2022. n.d. [cited 2024 Sep 30]. https://www.bps.go.id/id/statistics-table/2/MTc3OCMy/jumlah-kabupaten-kota-endemis-filariasis-yang-mencapai-eliminasi.html
- 11.World Health Organization. Monitoring and epidemiological assessment of mass drug administration in the global programme to eliminate lymphatic filariasis: a manual for national elimination programmes. Geneva: World Health Organization. 2011. https://iris.who.int/handle/10665/44580 [Google Scholar]
- 12.Rahmah N, Shenoy RK, Nutman TB, Weiss N, Gilmour K, Maizels RM, et al. Multicentre laboratory evaluation of Brugia Rapid dipstick test for detection of brugian filariasis. Trop Med Int Health. 2003;8(10):895–900. doi: 10.1046/j.1365-3156.2003.01102.x [DOI] [PubMed] [Google Scholar]
- 13.Jamail M, Andrew K, Junaidi D, Krishnan AK, Faizal M, Rahmah N. Field validation of sensitivity and specificity of rapid test for detection of Brugia malayi infection. Trop Med Int Health. 2005;10(1):99–104. doi: 10.1111/j.1365-3156.2004.01334.x [DOI] [PubMed] [Google Scholar]
- 14.Haarbrink M, Terhell A, Abadi K, van Beers S, Asri M, Yazdanbakhsh M. IgG4 antibody assay in the detection of filariasis. Lancet. 1995;346(8978):853–4. doi: 10.1016/s0140-6736(95)91676-8 [DOI] [PubMed] [Google Scholar]
- 15.Supali T, Rahmah N, Djuardi Y, Sartono E, Rückert P, Fischer P. Detection of filaria-specific IgG4 antibodies using Brugia Rapid test in individuals from an area highly endemic for Brugia timori. Acta Trop. 2004;90(3):255–61. doi: 10.1016/j.actatropica.2004.02.001 [DOI] [PubMed] [Google Scholar]
- 16.Djuardi Y, Jannah IF, Supali T. IgG4 antibodies against Bm14 as an evaluation tool of mass drug administration in a co-endemic area of Brugia timori and Wuchereria bancrofti. Acta Trop. 2022;227:106278. doi: 10.1016/j.actatropica.2021.106278 [DOI] [PubMed] [Google Scholar]
- 17.Mahanty S, Day KP, Alpers MP, Kazura JW. Antifilarial IgG4 antibodies in children from filaria-endemic areas correlate with duration of infection and are dissociated from antifilarial IgE antibodies. J Infect Dis. 1994;170(5):1339–43. doi: 10.1093/infdis/170.5.1339 [DOI] [PubMed] [Google Scholar]
- 18.Reszon Diagnostics International Sdn. Bhd. Brugia Rapid (A New Innovative Test for Diagnosis of Brugian Filariasis). 2014 [cited 2024 Dec 4]. https://www.reszonics.com/wp-content/uploads/2017/04/Reszon-IFU-Brugia-Rapid-2014-06.pd
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Instructions for use with whole blood and dried blood spot (DBS) samples.
(PDF)
This file contains data from survey 2 (communities and school children) used for figures and tables.
(XLSX)
Data Availability Statement
All relevant data are within the manuscript and its Supporting Information files.




